Key result
Late intravenous thrombolysis improves 90-day functional recovery by ~22% in imaging-selected stroke.
Why the study?
Intravenous thrombolysis has traditionally been limited to within 4.5 hours after stroke onset, potentially excluding patients with salvageable brain tissue identified by advanced imaging beyond this window.
Does intravenous thrombolysis improve functional outcomes in imaging-selected acute ischemic stroke patients presenting beyond 4.5 hours?
Meta-Analysis (n=4,192)
Does intravenous thrombolysis improve functional outcomes in imaging-selected acute ischemic stroke patients presenting beyond 4.5 hours?
Relative Risk: 1.22 (95% CI 1.16–1.29)
Intravenous thrombolysis guided by multimodal imaging extends the treatment window for acute ischemic stroke beyond 4.5 hours, significantly improving functional outcomes despite an increased risk of intracranial hemorrhage.
Supports extending thrombolysis beyond 4.5 hours in imaging-selected stroke; extends evidence for penumbra-guided selection.
BACKGROUND: Intravenous thrombolysis is a standard treatment for acute ischemic stroke but has traditionally been limited to 4.5 hours after symptom onset. This time-based restriction may exclude patients with salvageable brain tissue, especially those with wake-up or unknown-onset strokes. Multimodal imaging allows for the identification of viable penumbra beyond traditional treatment windows. This study compiles randomized evidence evaluating intravenous thrombolysis in imaging-selected patients treated after 4.5 hours. METHODS: We conducted a systematic review and meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Embase, and Cochrane Central were searched through February 2026 for randomized trials comparing intravenous thrombolysis (alteplase or tenecteplase) with best medical therapy in patients presenting beyond 4.5 hours or with wake-up/unknown-onset stroke selected by imaging. The primary outcome was excellent functional outcome at 90 days (modified Rankin Scale score 0–1). Secondary outcomes included functional independence (modified Rankin Scale score 0–2), symptomatic intracranial hemorrhage, and 90-day mortality. RESULTS: Fourteen trials involving 4192 participants were analyzed. Intravenous thrombolysis improved excellent functional outcomes (modified Rankin Scale score 0–1; risk ratio, 1.22 [95% CI, 1.16–1.29]) and functional independence (modified Rankin Scale score 0–2; risk ratio, 1.12 [95% CI, 1.06–1.18]). Both alteplase and tenecteplase contributed to these benefits. Thrombolysis increased the risk of symptomatic intracranial hemorrhage (risk ratio, 2.58 [95% CI, 1.58–4.22]) but did not significantly affect 90-day mortality (risk ratio, 1.15 [95% CI, 0.97–1.35]). CONCLUSIONS: In patients selected using advanced imaging, intravenous thrombolysis performed after 4.5 hours improves functional outcomes without increasing mortality, supporting a tissue-based rather than strictly time-based approach to treating acute ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Velammal et al. (2026) conducted a meta-analysis in Acute ischemic stroke (n=4,192). Intravenous thrombolysis (alteplase or tenecteplase) vs. Best medical therapy was evaluated on Excellent functional outcome at 90 days (modified Rankin Scale score 0–1) (RR 1.22, 95% CI 1.16-1.29). Intravenous thrombolysis performed after 4.5 hours in imaging-selected acute ischemic stroke patients improved excellent functional outcomes at 90 days (RR 1.22; 95% CI 1.16-1.29).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: